MedTrace Logo

Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia

NCT07490327 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-24

No results posted yet for this study

Summary

This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.

Conditions

Interventions

DRUG

AD-303A

Topical AD-303A applied to the scalp according to the study protocol.

DRUG

AD-3031

Oral AD-3031 administered according to the study protocol.

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Moogene Medi Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Seung Hwan Lee, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07490327 on ClinicalTrials.gov